Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Land & Improvements (2016 - 2023)

Historic Land & Improvements for China Pharma Holdings (CPHI) over the last 15 years, with Q2 2023 value amounting to $389808.0.

  • China Pharma Holdings' Land & Improvements fell 711.89% to $389808.0 in Q2 2023 from the same period last year, while for Jun 2023 it was $389808.0, marking a year-over-year decrease of 711.89%. This contributed to the annual value of $404427.0 for FY2022, which is 845.57% down from last year.
  • China Pharma Holdings' Land & Improvements amounted to $389808.0 in Q2 2023, which was down 711.89% from $409895.0 recorded in Q1 2023.
  • Over the past 5 years, China Pharma Holdings' Land & Improvements peaked at $443697.0 during Q1 2022, and registered a low of $389808.0 during Q2 2023.
  • In the last 5 years, China Pharma Holdings' Land & Improvements had a median value of $413603.0 in 2020 and averaged $416443.1.
  • In the last 5 years, China Pharma Holdings' Land & Improvements soared by 958.79% in 2021 and then crashed by 865.37% in 2022.
  • China Pharma Holdings' Land & Improvements (Quarter) stood at $403755.0 in 2019, then grew by 6.92% to $431681.0 in 2020, then rose by 2.34% to $441783.0 in 2021, then decreased by 8.46% to $404427.0 in 2022, then fell by 3.61% to $389808.0 in 2023.
  • Its last three reported values are $389808.0 in Q2 2023, $409895.0 for Q1 2023, and $404427.0 during Q4 2022.